Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -72,10 +72,8 @@
72	72
73	73	== International business ==
74	74
75		-Total sales from international business for FY 2020 stood at H 1,790 cr. against H 1,324 cr. in the previous year, a growth of 35%. It was primarily backed by robust growth of 82% in the US market and strong growth in branded generics at 27% in Asia and 14% in Africa.
	75	+Total sales from international business for FY 2020 stood at H 1,790 cr. against H 1,324 cr. in the previous year, a growth of 35%. It was primarily backed by robust growth of 82% in the US market and strong growth in branded generics at 27% in Asia and 14% in Africa. Company’s exports revenues are contributed by well-diversified markets, avoiding over dependence on any single market.
76	76
77		-As explained in Exhibit 4 and Exhibit 5, company’s exports revenues are contributed by well-diversified markets, avoiding over dependence on any single market.
78		-
79	79	= Financial highlight =
80	80
81	81	April 30, 2020 Ajanta Pharma Ltd. reported performance for the 4 th quarter & financial year ended 31 st March 2019.{{footnote}}http://www.ajantapharma.com/AdminData/Results/PressReleaseandResultQ4FY2019.pdf{{/footnote}}